Compare CDXS & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDXS | SENS |
|---|---|---|
| Founded | 2002 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Industrial Machinery/Components |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.3M | 301.2M |
| IPO Year | 2008 | 2014 |
| Metric | CDXS | SENS |
|---|---|---|
| Price | $1.58 | $9.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | ★ 1.0M | 782.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.82 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $138,590,000.00 | $16,389,000.00 |
| Revenue This Year | $7.73 | $74.15 |
| Revenue Next Year | $14.24 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | 19.85 |
| 52 Week Low | $0.96 | $0.41 |
| 52 Week High | $2.98 | $9.99 |
| Indicator | CDXS | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 47.97 | 74.02 |
| Support Level | $1.57 | $5.13 |
| Resistance Level | $1.75 | N/A |
| Average True Range (ATR) | 0.10 | 0.54 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 67.21 | 77.33 |
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.